Daily Archives: April 17, 2019

Mobile Network Operators Struggle to Prepare for 5G

Infovista survey at MWC 2019 shows only 1 in 4 MNOs feel extremely prepared for 5G, lists top concerns and challenges

ASHBURN, Va., April 17, 2019 (GLOBE NEWSWIRE) — A new survey from Infovista, the leader in modern network performance, finds that only 25 percent of mobile network operators say they are extremely prepared for 5G, citing as their top concerns making sure their 5G network works correctly, the rollout stays within budgets, not being late to market and that the network meets subscriber needs. The survey also found that even fewer vendors who work with Mobile World Operators (MNOs) (just 1 in 6) feel MNOs are extremely prepared for 5G.

Tweet This: Infovista Survey finds Mobile Operators Struggle to Prepare for #5G: https://www.infovista.com/blog/recent-survey-finds-mobile-network-operators-struggling-to-prepare-for-5g

Infovista conducted the survey at MWC 2019 in Barcelona in February. The survey polled 145 attendees including MNOs, companies that work with MNOs and enterprises looking to adopt 5G networks. Respondents came from 22 countries.

“Rolling out a new 5G network is a complex endeavor,” says Adrian Jakobsson, Sr. VP of Strategy at Infovista. “The penalties for failure — being late to market or not meeting network goals – are extreme. We’re not surprised to see so much concern amongst MNOs.”

RESULTS

5G Brings Challenges for MNOs
5G has great potential, but it also brings challenges. The biggest challenges MNOs say they are facing as they work to roll out their 5G networks include the following:

  • Planning & optimizing the radio access network
  • Setting-up efficient operations
  • Planning & optimizing microwave and backhaul networks
  • Network testing, troubleshooting and optimizing the 5G networks once it is rolled out
  • Densifying the networks

5G is Important to Enterprises
5G capabilities should make end users’ lives easier, enhance business communications and expand IoT’s potential. Two-thirds of enterprises surveyed report 5G is somewhat to extremely important to their futures. The top applications reported for 5G include the following:

  • Collecting data from IoT devices
  • Sensors and IoT
  • Smart homes
  • Industrial IoT

Enterprises also report the most important markets for 5G include:

  • Media, entertainment or gaming
  • Automotive
  • Public safety
  • Retail

Enterprises Expect Their MNOs to Keep-up
Once 5G arrives, 3 in 4 enterprises responded that it’s important for their MNO to fully support the 5G standard. MNO respondents understand the importance of delivering 5G services with 4 in 5 MNOs reporting that 5G is somewhat to extremely important to their future. In addition, MNOs report the top reasons for pursuing 5G include the following:

  • Addressing “over-the-top” issues
  • Increasing market share
  • Adding new billable services

Keys for Success
For 5G to thrive, it is important for MNOs to take the following steps:

  • Make the right decisions for 5G investment, including adopting data-driven processes
  • Focus on increasing your efficiency across the board to increase network agility
  • Guarantee a powerful customer experience by leveraging network data and predictive methodologies
  • Exploit the high potential of 5G to generate new revenues (new verticals)

About Infovista
Infovista, the leader in modern network performance, provides complete visibility and unprecedented control over modern networks and their applications. Infovista delivers brilliant user experiences and maximum value for networks and applications. At the core of its approach are data and analytics, to give service providers and enterprises real-time insights to make critical business decisions. Infovista offers a comprehensive line of solutions from the radio network to enterprise to device throughout the lifecycle of a network. No other solutions provider has this totality of vision. More than 1,500 enterprises and service providers around the world—including 250 of the world’s top mobile network operators—rely on Infovista. Know Your Network with Infovista.

Contact Us:
Infovista
Henry Chalian
703-707-1742
Henry.chalian@infovista.com

SNOMED International’s Global Patient Set: Navigating International Patient Care and Interoperability

LONDON, April 17, 2019 (GLOBE NEWSWIRE) — At SNOMED International’s April Business Meeting held in London last week, the organization announced to its Community of Practice the planned release of a Global Patient Set built from its globally recognized SNOMED CT clinical terminology standard.

SNOMED International will release the Global Patient Set, or GPS, to support the cross border movement of information, and ultimately health system interoperability. Once released, the GPS, a controlled list of existing SNOMED CT unique concept identifiers, single descriptions and reference sets, will be available to all interested parties at no cost to users.

The Chair of the organization’s General Assembly, Lies van Gennip, is delighted to share with health systems and industry what the Global Patient Set provides to Members and non-Members alike. “The Global Patient Set enables easier specification of EHR requirements, e.g. a patient summary, and results in improved interoperability. The Set will also offer non-Members considering SNOMED CT use a mechanism for greater insight into the product and its value without requiring initial investment.”

CEO, Don Sweete, emphasizes that the release of the GPS serves as a stepping stone to leverage the true value of SNOMED CT’s polyhierarchical design. “An innovative offering, it is worth noting that the Global Patient Set offers a limited function of SNOMED CT. Providing a flat list of existing concepts and reference sets, the GPS is positioned to support cross border interoperability and enhanced digital maturity as users move towards decision support and full analytics capabilities in their respective strategies,” said Sweete in his discussions with the SNOMED CT Community of Practice last week.

Chief among its advantages, SNOMED International Members benefit from a terminology that enables interoperability, reduced clinical risk, large scale public health reporting and research, along with a wealth of organization resources including education, tooling, creation of national extensions, representation on governance bodies, and dedicated on-boarding and user support.

Over the coming months, SNOMED International will formalize the steps and due diligence required to make the GPS offering available for release September 1, 2019. Throughout this period, SNOMED International will continue to define the Global Patient Set, from content through to its release and maintenance approach. Refer to SNOMED International’s Global Patient Set resources to learn more as this initiative progresses. Subscribe with the organization’s news service to keep up to date on developments as they occur.

For additional information, contact info@snomed.org.

About SNOMED International
SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, the world’s most comprehensive healthcare terminology product. We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms. This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community. SNOMED International is the trading name of the International Health Terminology Standards Development Organisation.
www.snomed.org

Media Inquiries:
Kelly Kuru, Executive Lead, Communications
SNOMED International
Telephone: +1-416-566-8725 (Canada)
Email: kku@snomed.org

QuantuMDx Group Ltd has announced plans to expand the potential of its Q-POC™ technology and develop a quality control analytics system for cell and gene therapies (“C&GT”s), to be evaluated by GlaxoSmithKline’s C&GT platform group.

Press Release: 17 April 2019

QuantuMDx Group Ltd has announced plans to expand the potential of its Q-POC™ technology and develop a quality control analytics system for cell and gene therapies (“C&GT”s), to be evaluated by GlaxoSmithKline’s C&GT platform group.

Quality control testing for autologous C&GT’s can be challenging as they are manufactured in small batches and personalised to each patient. However, the C&GT industry is accustomed to manufacturing therapies in large batches, for the treatment of tens of thousands of patients. Within this context, the ability to provide rapid throughput, lab-standard and decentralised safety testing and analytics, on a batch by batch basis, could offer considerable benefits.

QuantuMDx has developed the Q-POC™: a portable DNA analyser which compresses multiple molecular diagnostics laboratories into an affordable, simple-to-use, highly multiplexed and connected device. The Q-POC™ can be used in many environmental settings, providing results in 20 minutes and offers a potential analytical solution for the manufacture of autologous C&GTs.

Following encouraging proof of concept data, QuantuMDx is now developing a sample-to-result mycoplasma assay cassette – using PCR – to run on the Q-POC™ reader.

QuantuMDx will develop the novel technology ready for evaluation and validation by GlaxoSmithKline’s C&GT platform group.

Jonathan O’Halloran, Chief Scientific Officer at QuantuMDx Group said:

“We’re delighted to be able to work with GSK in the development of analytical solutions for autologous ex vivo gene therapies using our Q-POC™ diagnostic device. The Q-POC™ is designed to provide rapid, lab-standard molecular diagnostics at the point of care and we’re excited by its potential to support C&GT safety testing, automate processes and help bridge this analytical gap.”

Jonathan added: “This co-development also highlights wider opportunities for QuantuMDx and the Q-POC™ in applied markets.”

More information:

Autologous ex vivo gene therapy is a novel personalised treatment approach that can be used to address disorders using a patient’s own cells. Cells are taken from the patient and genetically corrected or modified outside of the body. The genetically corrected or modified cells are then transplanted back into the patient, providing a perfect biological match.

About QuantuMDx Group

QuantuMDx Group is a multinational company with a global vision: to revolutionise healthcare and help eradicate disease by making accurate diagnostics universally accessible.

In the past, patients have had to wait days or even weeks for the results of diagnostic tests to come through, delaying treatment and increasing anxiety. QuantuMDx has overcome these barriers by innovating the entire molecular diagnostics process.

The company’s flagship device, the Q-POC™, compresses a molecular diagnostics laboratory into a simple-to-use, portable, affordable device. It can be used anywhere from basic under-the-tree settings to clinics and hospitals, providing results within 30 minutes.

Headquartered in the UK, QuantuMDx has operations and global partnerships with healthcare providers in the United States, Asia, Europe and Africa – keeping it at the forefront of molecular diagnostics.

For media enquiries:

Debra Daglish, Marketing Communications Manager, QuantuMDx Group, 0870 803 1234

Komet Announces Sales of its Assets in Burkina Faso

QUÉBEC CITY, April 16, 2019 (GLOBE NEWSWIRE) — Komet Resources Inc. (“Komet” or the “Corporation”) wishes to announce that it has entered into an agreement to sell all the issued and outstanding shares that it holds in the share capital of its subsidiaries in Burkina Faso (the “Share Disposition”), Komet Ressources Afrique SA and Guiro Exploration SARL (the “Subsidiaries”), to CINI Solutions, a private corporation located in Qatar (“CINI”).

CINI will pay the following consideration to Komet for the Share Disposition: (i) the assumption of all the debts of the Subsidiaries; (ii) 12 consecutive monthly payments of US$100,000 to Komet. Closing of the transaction is expected to occur at the end of April. CINI also holds a first right of offer on the Dabia South property in Mali until June 7, 2019 in consideration for a single cash payment of US$7,000,000.

This transaction will allow Komet to cease all activities in Burkina Faso. The Corporation now intends on further developing its Dabia South property in Mali and will also focus its efforts on acquiring gold and base metal exploration and development opportunities in eastern Canada.

For more Information on Komet Resources Inc.:
Lucas Werner Claessens
Chief Executive Officer
Email: lw.claessens@kometgold.com
Tel: +1-647-647-2285

Investors relations:
Carl Desjardins, Relations publiques Paradox inc.
Email: carldesjardins@paradox-pr.ca
Tel: +1-514-341-0408

About Komet Resources
Komet Resources Inc. is a Canadian-based gold mining and exploration Corporation, listed on the TSX-V, with a focus on exploration of its projects in Mali, West Africa.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.